Get the Stockscreener App
59.14
0.15%
0.09
After Hours:
59.14
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $59.14, with a volume of 7.92M.
It is up +0.15% in the last 24 hours and up +5.49% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$59.05
Open:
$59.29
24h Volume:
7.92M
Relative Volume:
0.79
Market Cap:
$119.95B
Revenue:
$47.44B
Net Income/Loss:
$-7.26B
P/E Ratio:
-16.47
EPS:
-3.59
Net Cash Flow:
$13.80B
1W Performance:
+0.00%
1M Performance:
+5.49%
6M Performance:
+20.57%
1Y Performance:
+19.74%
1-Day Range:
$58.58
$59.35
1-Week Range:
$58.58
$61.10
52-Week Range:
$39.35
$61.10
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.14 | 119.95B | 47.44B | -7.26B | 13.80B | -3.59 |
|
LLY
Lilly Eli Co
|
823.23 | 782.40B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.34 | 378.88B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
152.87 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
175.65 | 310.40B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.95 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
New England Research & Management Inc. Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Gries Financial LLC Increases Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Milestone Asset Management LLC Takes $1.51 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Asset Dedication LLC Has $819,000 Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Nilsine Partners LLC Invests $357,000 in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (BMY) Projected to Post Earnings on Thursday - MarketBeat
Why Bristol-Myers Squibb Company (BMY) Is the Best Blue Chip Stock to Buy Under $100? - Insider Monkey
Bristol-Myers Squibb's SWOT analysis: stock faces challenges amid growth prospects - Investing.com
Bristol-Myers Squibb (BMY): Cramer’s Old-School Move for DeepSeek Market Jitters - Insider Monkey
12 Best Blue Chip Stocks to Buy Under $100 - Insider Monkey
How To YieldBoost Bristol Myers Squibb From 4.2% To 8.9% Using Options - Nasdaq
Swedbank AB Purchases 46,122 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Forsta AP Fonden Cuts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Position Lessened by YHB Investment Advisors Inc. - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $65.00 at Citigroup - MarketBeat
3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average - The Motley Fool
Is Bristol-Myers Squibb Company (BMY) the Safe Stock to Buy for the Long Term in 2025? - Insider Monkey
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Industry Groups Push to Dismiss PRT Lawsuit Against Bristol-Myers Squibb - PLANADVISER
Bristol-Myers Squibb (NYSE:BMY) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Deep Dive Into Bristol-Myers Squibb Stock: Analyst Perspectives (9 Ratings) - Benzinga
Buffington Mohr McNeal Purchases Shares of 4,234 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today - Yahoo Finance UK
REIT Alexandria Real Estate posts higher Q4 FFO on resilient leasing demand - Reuters
Bristol-Myers Squibb (NYSE:BMY) Reaches New 12-Month HighWhat's Next? - MarketBeat
Parsons Capital Management Inc. RI Sells 4,665 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yahoo Finance
Parkside Investments LLC Lowers Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Hunter Perkins Capital Management LLC Has $10.10 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
BMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts - BioSpace
KBC Group NV Buys 628,908 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
PFG Investments LLC Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Stonehage Fleming Financial Services Holdings Ltd Takes Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Dynamic Advisor Solutions LLC Decreases Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy... - BioSpace
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by 1834 Investment Advisors Co. - MarketBeat
4,724 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Guerra Pan Advisors LLC - MarketBeat
First Citizens Bank & Trust Co. Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Moody Lynn & Lieberson LLC Grows Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Insight Inv LLC Grows Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Advocate Group LLC Increases Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Toth Financial Advisory Corp Has $4.13 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by AEGON ASSET MANAGEMENT UK Plc - MarketBeat
Grimes & Company Inc. Cuts Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Goelzer Investment Management Inc. Sells 4,529 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Cornerstone Wealth Management LLC - MarketBeat
Employer Groups Back Tossing Pension Annuity Suit In NY - Law360
Industry Groups Urge Dismissal of PRT Lawsuit Against Bristol-Myers Squibb - PLANSPONSOR
Enabling early lung cancer screening for veterans - Bristol Myers Squibb
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):